Transforming Blood Cancer Care: The Role of Clinical Trials and CAR T-Cell Therapy

Continuing Education Overview

Target Audience
This activity has been designed to meet the educational needs of nurses involved in the care of patients with hematologic cancers and oncology social workers at intermediate and advanced levels of practice.

Program Goal
To provide an opportunity for nurses and social workers caring for patients with hematologic malignancies to expand their knowledge of treatment and side-effect management through case studies.

MEDIUM: Virtual Lecture
INTERNET RELEASE DATE: August 23, 2016
CE AVAILABLE UNTIL: February 23, 2018

Program Overview
There has been great progress in treatment, but for most blood cancers, there is no cure and better therapies are needed. In this activity, new and evolving treatment strategies will be discussed, including how the heterogeneous nature of blood cancers dictates treatment and prognosis, the role of clinical trials, and the evolving role of CAR T-cell therapy. Case studies will focus on acute myeloid leukemia (AML) and on diffuse large B-cell lymphoma (DLBCL). Treatment and side-effect management and communication with patients about clinical trials will be highlighted. Interactive discussions will be incorporated throughout this activity.

Education Objectives
At the conclusion of this program, participants should be able to:

Explain how the heterogeneous nature of blood cancers dictates treatment and prognosis
Describe the evolving role of CAR-T cell therapy in treating blood cancers
Educate patients about participation in a clinical trial

Continuing Education Information
Approval for nurses has been obtained by the LLS National Office under provider number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

The Leukemia & Lymphoma Society (LLS), provider number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org Approved Continuing Education Program (ACE). Approval Period: December 10, 2017-December 10, 2020. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 1.0 clinical CE contact hour.

LLS is recognized by the New York State Education Department's State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.0 clinical CE contact hour for this activity.

There is no fee for this education activity.

Faculty Disclosures
All faculty participating in continuing education by The Leukemia & Lymphoma Society are expected to disclose to the activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) disclosed in their presentations.

Brenna Hansen, BSN, RN, OCN^®
Monica Kwari, RN, BSN, CCRP
Margaret McCormick, RN, BSN, MA, MBA
Have no affiliations with commercial interests to disclose

Assistance for people with disabilities, grievances, questions or for more information on LLS programs, please call an LLS Information Specialist toll-free at (800) 955-4572.


Continuing Education Overview Target Audience This activity has been designed to meet the educational needs of nurses involved in the care of patients with hematologic cancers and oncology social workers at intermediate and advanced levels of practice. Program Goal To provide an opportunity for nurses and social workers caring for patients with hematologic malignancies to expand their knowledge of treatment and side-effect management through case studies. MEDIUM: Virtual Lecture INTERNET RELEASE DATE: August 23, 2016 CE AVAILABLE UNTIL: February 23, 2018 Program Overview There has been great progress in treatment, but for most blood cancers, there is no cure and better therapies are needed. In this activity, new and evolving treatment strategies will be discussed, including how the heterogeneous nature of blood cancers dictates treatment and prognosis, the role of clinical trials, and the evolving role of CAR T-cell therapy. Case studies will focus on acute myeloid leukemia (AML) and on diffuse large B-cell lymphoma (DLBCL). Treatment and side-effect management and communication with patients about clinical trials will be highlighted. Interactive discussions will be incorporated throughout this activity. Education Objectives At the conclusion of this program, participants should be able to: Explain how the heterogeneous nature of blood cancers dictates treatment and prognosis Describe the evolving role of CAR-T cell therapy in treating blood cancers Educate patients about participation in a clinical trial Continuing Education Information Approval for nurses has been obtained by the LLS National Office under provider number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing. The Leukemia & Lymphoma Society (LLS), provider number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org Approved Continuing Education Program (ACE). Approval Period: December 10, 2017-December 10, 2020. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 1.0 clinical CE contact hour. LLS is recognized by the New York State Education Department's State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.0 clinical CE contact hour for this activity. There is no fee for this education activity. Faculty Disclosures All faculty participating in continuing education by The Leukemia & Lymphoma Society are expected to disclose to the activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) disclosed in their presentations. Brenna Hansen, BSN, RN, OCN^® Monica Kwari, RN, BSN, CCRP Margaret McCormick, RN, BSN, MA, MBA Have no affiliations with commercial interests to disclose Assistance for people with disabilities, grievances, questions or for more information on LLS programs, please call an LLS Information Specialist toll-free at (800) 955-4572.